Flynn Jeffrey C, Gilbert Jacqueline A, Meroueh Chady, Snower Daniel P, David Chella S, Kong Yi-chi M, Banga J Paul
Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, MI, USA.
Immunology. 2007 Oct;122(2):261-7. doi: 10.1111/j.1365-2567.2007.02635.x. Epub 2007 May 29.
We have examined the induction of autoimmunity and the maintenance of sustained hyperthyroidism in autoimmunity-prone human leucocyte antigen (HLA) DR3 transgenic non-obese diabetic (NOD) mice following chronic stimulation of the thyrotropin receptor (TSHR) by monoclonal thyroid-stimulating autoantibodies (TSAbs). Animals received weekly injections over the course of 9 weeks of monoclonal antibodies (mAbs) with strong thyroid-stimulating properties. Administration of the mAbs KSAb1 (IgG2b) or KSAb2 (IgG2a), which have similar stimulating properties but different TSH-binding blocking activity, resulted in significantly elevated serum thyroxine (T(4)) levels and thyroid hyperplasia. After the first injection, an initial surge then fall in serum T(4) levels was followed by sustained elevated levels with subsequent injections for at least 63 days. Examination of KSAb1 and KSAb2 serum bioactivity showed that the accumulation of the TSAbs in serum was related to their subclass half-lives. The thyroid glands were enlarged and histological examination showed hyperplastic follicles, with minimal accompanying thyroid inflammation. Our results show that chronic in vivo administration of mAbs with strong thyroid-stimulating activity resulted in elevated T(4) levels, suggesting persistent stimulation without receptor desensitization, giving a potential explanation for the sustained hyperthyroid status in patients with Graves' disease. Moreover, despite the presence of HLA disease susceptibility alleles and the autoimmune prone NOD background genes, chronic stimulation of the thyroid gland did not lead to immune cell-mediated follicular destruction, suggesting the persistence of immunoregulatory influences to suppress autoimmunity.
我们研究了在自身免疫易感性人类白细胞抗原(HLA)DR3转基因非肥胖糖尿病(NOD)小鼠中,单克隆甲状腺刺激自身抗体(TSAbs)对促甲状腺素受体(TSHR)进行慢性刺激后自身免疫的诱导以及持续性甲状腺功能亢进的维持情况。在9周的时间里,动物每周接受具有强烈甲状腺刺激特性的单克隆抗体(mAbs)注射。给予具有相似刺激特性但TSH结合阻断活性不同的mAbs KSAb1(IgG2b)或KSAb2(IgG2a),导致血清甲状腺素(T4)水平显著升高以及甲状腺增生。首次注射后,血清T4水平先出现一个初始高峰然后下降,随后的注射使其持续升高至少63天。对KSAb1和KSAb2血清生物活性的检测表明,血清中TSAbs的积累与其亚类半衰期有关。甲状腺肿大,组织学检查显示滤泡增生,伴有轻微的甲状腺炎症。我们的结果表明,体内长期给予具有强烈甲状腺刺激活性的mAbs会导致T4水平升高,提示持续刺激而无受体脱敏,这为格雷夫斯病患者的持续性甲状腺功能亢进状态提供了一种潜在解释。此外,尽管存在HLA疾病易感等位基因和自身免疫易感性NOD背景基因,但甲状腺的慢性刺激并未导致免疫细胞介导的滤泡破坏,这表明存在免疫调节影响以抑制自身免疫。